Therapeutic drugs in the treatment of symptomatic uterine fibroids

Bibliography

• Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004;104:393-406
   PubMed Web of Science ®Google Scholar
• Jacoby VL, Fujimoto VY, Giudice LC, et al. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 2010;202:514-21
   PubMed Web of Science ®Google Scholar
• Islam MS, Protic O, Giannubilo SR, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013;98:921-34
   PubMed Web of Science ®Google Scholar
• Bouchard P. Current and future medical treatments for menometrorrhagia during the premenopause. Gynecol Endocrinol 2011;27(Suppl 1):1120-5
   Google Scholar
• Eckey T, Neumann A, Bohlmann M.K, et al. Non invasive termoablation of symptomatic uterine fibroids with magnetic resonance guided high energetic ultrasound. Radiologe 2011;51:610-19
   Google Scholar
• Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001;CD000547
   Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32
   PubMed Web of Science ®Google Scholar
• Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:571-88
   PubMed Web of Science ®Google Scholar
• Nierth-Simpson EN, Martin MM, Chiang TC, et al. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology 2009;150:2436-45
   PubMed Web of Science ®Google Scholar
• Blake RE. Leiomyomata uteri: hormonal and molecular determinants of growth. J Natl Med Assoc 2007;99:1170-84
   PubMed Web of Science ®Google Scholar
• Tsiligiannis SE, Zaitseva M, Coombs PR, et al. Fibroid-associated heavy menstrual bleeding: correlation between clinical features, Doppler ultrasound assessment of vasculature, and tissue gene expression profiles. Reprod Sci 2013;20:361-70
   PubMed Web of Science ®Google Scholar
• Romer TH-JA, Ahrend HJ, Rabe T. Medikamentöse therapie von myomen. Frauenarzt 2013;54:374-9
   Google Scholar
• Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85
   PubMed Web of Science ®Google Scholar
• Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-24
   PubMed Web of Science ®Google Scholar
• Farquhar C, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009;CD004143
   PubMed Web of Science ®Google Scholar
• Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986;293:359-62
   PubMed Web of Science ®Google Scholar
• Romer T. Benefit of GnRH analogue pretreatment for hysteroscopic surgery in patients with bleeding disorders. Gynecol Obstet Invest 1998;45(Suppl 1):12-20; discussion 1, 35
   Google Scholar
• Ito M, Sakoda Y, Okamura H. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma. Endocrinol Jpn 1990;37:907-13
   Google Scholar
• Broekmans FJ. GnRH agonists and uterine leiomyomas. Hum Reprod 1996;11(Suppl 3):3-25
   PubMedGoogle Scholar
• Fedele L, Bianchi S, Baglioni A, et al. Intranasal buserelin versus surgery in the treatment of uterine leiomyomata: long-term follow-up. Eur J Obstet Gynecol Reprod Biol 1991;38:53-7
   Google Scholar
• Matta WH, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989;96:200-6
   PubMedGoogle Scholar
• De Falco M, Staibano S, Mascolo M, et al. Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol 2009;144:44-7
   PubMedGoogle Scholar
• Palomba S, Orio F Jr, Russo T, et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 2004;19:1308-14
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Acosta R, Perez Y, et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int J Womens Health 2013;5:115-24
   PubMedGoogle Scholar
• Tristan M, Orozco LJ, Steed A, et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev 2012;8:CD007687
   PubMed Web of Science ®Google Scholar
• Wilkens J, Williams AR, Chwalisz K, et al. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Hum Reprod 2009;24:1036-44
   PubMed Web of Science ®Google Scholar
• Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664-71
   PubMed Web of Science ®Google Scholar
• Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36
   PubMed Web of Science ®Google Scholar
• Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011;95:767-72; e1-2
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20
   PubMed Web of Science ®Google Scholar
• Brache V, Sitruk-Ware R, Williams A, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception 2012;85:480-8
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582-9
   PubMed Web of Science ®Google Scholar